Prostatilen
Research OnlyA peptide complex extracted from bovine prostate glands, developed in Russia and registered as a pharmaceutical for prostatitis treatment. Available as suppositories and injections in Russia and CIS countries. Has more clinical documentation than most bioregulators but lacks Western validation.
Prostate peptide extract · Samprost · Vitaprost · Prostate cytamins
8 human studies
- Preclinical
- 39%
- Clinical
- 44%
Based on 18 cited sources
clinically demonstrated · low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 64 (1A 28: single Phase III randomized multicenter open-label RCT n=98, Prostatilen AC vs Prostatilen, 36318852; 1B 9: best study only open-label/"some concerns", no blinded placebo arm; 1C 9: cumulative human N well over 1,000 across Tkachuk n=307 / 1823682 and Al-Shukri n=1115 / 14708243 but heterogeneous and mostly uncontrolled; 1D 12: direct population/route/outcome match — prostatitis & BPH patients, suppository/IM, symptom endpoints; 1E 6: modest multi-model preclinical program — rat prostatic hyperplasia 16027846, rat/cat smooth muscle 10050514, lymphatic vessels). Mechanism 32 (2A 10: undefined bovine-prostate peptide mixture, target inferred from tissue tropism with no measured binding; 2B 8: proximal signaling partially known — cytokine modulation, smooth-muscle contractility, lactoferrin normalization 9412014 — but chain hand-wavy for an undefined extract; 2C 6: concentration-dependent in-vitro chronotropic effect; 2D 8: confirmed in in-vivo mammalian models). Plausibility 61 (3A 22: mechanism→surrogate established (inflammation markers, microcirculation 14708243), surrogate→symptom benefit inferred; 3B 19: anti-inflammatory and trophic prostate actions cohere with prostatitis/BPH biology; 3C 11: analogous tissue-extract bioregulators show comparable tissue-specific effects, mixed; 3D 9: moderately broad claim spanning inflammation, microcirculation, immune and reproductive endpoints). Global Coverage 44 (4A 13: multiple author groups but one Russian/CIS research tradition, no independent Western replication; 4B 9: Russia, Ukraine, Georgia — one geopolitical cluster; 4C 12: ~18 directly relevant studies of moderate diversity; 4D 10: registered pharmaceutical with one national regulator (Russia)). Community Experience 42 (5A 6: negligible documented Western community/user discussion; 5B 15: >7-year sustained real-world clinical use since early-1990s registration; 5C 11: broadly consistent Russian clinical themes; 5D 10: Russian pharmacovigilance reports good tolerability, no recurring serious adverse signal). Effectiveness clinical, score 37, confidence low: human efficacy data exist (RCT 36318852 quantified sperm-parameter gains ~14% vs ~4%; observational symptom improvement) but effect sizes are modest, endpoints partly surrogate, and the absence of blinded placebo controls plus single-country open-label design inflates apparent benefit (E1 12 / E2 9 / E3 9 / E4 7).
The proposed mechanisms of Prostatilen are based primarily on Russian clinical and preclinical research. As a peptide complex rather than a single defined molecule, mechanisms are attributed to the collective action of multiple prostate-derived peptide fractions.
How It Works (Simplified)
Prostatilen targets prostate health through multiple proposed pathways:
Modulates inflammatory cytokines in prostate tissue, reducing chronic inflammation associated with prostatitis and BPH.
Improves blood flow to prostate tissue, potentially enhancing nutrient delivery and waste removal from the gland.
Affects smooth muscle tone in the prostate and lower urinary tract, potentially improving urinary flow and reducing symptoms.
Modulates local immune responses in prostate tissue, potentially normalizing immune-mediated inflammation.
Key Context: Prostatilen operates on the Russian “bioregulation” theory that tissue-specific peptides from one organism can support equivalent tissues in another. This theoretical framework has not been validated by Western biomedical research.
Important Limitations
- Not a defined molecule: Cannot characterize pharmacokinetics, binding sites, or precise mechanisms
- Bovine tissue source: Quality depends entirely on manufacturing standards and animal sourcing
- Russian research only: No independent Western validation of claimed mechanisms
- Translation uncertainty: Proposed mechanisms extrapolated from clinical outcomes, not molecular studies
- Standardization challenges: Peptide content may vary between batches
- Theoretical framework: “Bioregulation” theory not accepted in Western medicine
Comparison to Defined Peptides
Unlike synthetic peptides such as BPC-157, epithalon, or selank, Prostatilen:
| Aspect | Prostatilen | Synthetic Peptides |
|---|---|---|
| Composition | Variable mixture | Defined sequence |
| Quality control | Difficult | Straightforward |
| Mechanism study | Limited | Can be characterized |
| Batch consistency | Variable | Consistent |
| Regulatory path | Complex (biologics) | Clearer |
This distinction is critical when evaluating evidence and making comparisons to other peptides in the bioregulator field.
Based on Russian clinical protocols: Initial effects on inflammation markers may begin. Suppository formulations provide direct prostatic absorption. Some patients report early symptom relief.
PMID:1823682Continued anti-inflammatory effects. Russian studies typically report measurable improvements in urinary symptom and obstruction scores within weeks. Microcirculation effects developing.
PMID:17315707Standard Russian treatment course is 5-10 days for suppositories, with repeat courses. Most clinical improvements reported within this timeframe. Sustained use shows cumulative benefits in Russian data.
PMID:2058122Maintenance protocols in Russia involve periodic repeat courses. Long-term efficacy and safety data limited. Some Russian studies followed patients for 6-12 months with repeat treatments.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Thymalin
CompatibleBoth Russian bioregulator peptide complexes from the same research tradition. Thymalin targets immune modulation via thymus, Prostatilen targets prostate tissue. Often used together in Russian protocols.
Epithalon
CompatibleDifferent targets within Russian bioregulation framework - epithalon for cellular longevity via telomerase, Prostatilen for prostate-specific tissue support.
Vilon
CompatibleBoth Khavinson bioregulator peptides with distinct tissue targets. Vilon is a synthetic dipeptide for immune regulation, Prostatilen is a natural complex for prostate tissue.
BPC-157
CompatibleDifferent regenerative mechanisms - BPC-157 for systemic tissue healing via growth factor modulation, Prostatilen for prostate-specific tissue support.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Prostatilen
Related Peptides
CJC-1295
DAC:GRF · Modified GRF 1-29 · Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST · FS-344 · FS-315 +1
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2 · Pralmorelin · KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6 · SKF-110679 · Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG · Choriogonadotropin · Pregnyl +5
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin · HEX · Growth Hormone Releasing Hexapeptide +2
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.